Protease inhibitor-associated hypertriglyceridemia and diabetes mellitus in HIV-infected patients
Knobel, H.; Goday, A.; Grau, S.
Medicina Clinica 111(15): 599
1998
ISSN/ISBN: 0025-7753 PMID: 9859098 Document Number: 493436
Document emailed within 1 workday
Related Documents
Bunyaratvej, P.; Komindr, S.; Wisedpanichkij, R. 2000: Different reticulocyte volume in diabetes mellitus patients with and without hypercholesterolemia and/or hypertriglyceridemia Journal of the Medical Association of Thailand 83(7): 790-796Chronister, C.L.; Gurwood, A.S. 1998: Type 2 diabetes in association with HIV-1 protease inhibitors in HIV-infected patients Journal of the American Optometric Association 69(11): 695-698
Gaillard, M.C.; Reichberg, S.B.; Nogueira, C.M.; Kilroe-Smith, T.A. 1993: Differences in elastase-binding activity of alpha 1-protease inhibitor and alpha 2-macroglobulin for asthma patients and control subjects with various alpha 1-protease inhibitor phenotypes Clinical Chemistry 39(4): 675-679
Gianotti, N.; Poli, A.; Galli, M.; Pan, A.; Rizzardini, G.; Soria, A.; Viale, P.; Di Biagio, A.; Quirino, T.; Viganò, P.; Bonfanti, P.; d'Arminio Monforte, A.; Fortino, I.; Lazzarin, A. 2014: Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study New Microbiologica 37(4): 439-448
Vogelberg, K.H.; Scherff, R.; Schulze-Schleppinghoff, B. 1982: The influence of clofibrate on glucose metabolism in diabetes mellitus without endogenous hypertriglyceridemia Arzneimittel-Forschung 32(4): 413-416
Bard, J-Marie.; Lassalle, Régis.; Capeau, J.; Bach-Ngohou, K.; Nazih-Sanderson, Fçoise.; Rémy, Gérard.; Reynes, J.; Ecobichon, J-Luc.; Savès, M.; Raffi, Fçois. 2006: Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy Antiviral Therapy 11(3): 361-370
Saves, M.; Raffi, F.; Clevenbergh, P.; Marchou, B.; Waldner-Combernoux, A.; Morlat, P.; LeMoing, V.; Riviere, C.; Chene, G.; Leport, C.; The APROCOStudy Group, 2000: Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients Antimicrobial Agents and Chemotherapy 44(12): 3451-3455
Okada, S.; Ishii, K.; Tanokuchi, S.; Hamada, H.; Ichiki, K.; Ota, Z. 1995: Effect of an alpha-glucosidase inhibitor combined with sulphonylurea treatment on glucose metabolism in patients with non-insulin-dependent diabetes mellitus Journal of International Medical Research 23(4): 279-283
Okada, S.; Ishii, K.; Tanokuchi, S.; Hamada, H.; Ichiki, K.; Ota, Z. 1995: Effect of alpha-glucosidase inhibitor in combination with sulphonylurea compounds on lipid profile in patients with non-insulin-dependent diabetes mellitus Journal of International Medical Research 23(6): 492-496
Fujii, Y.; Matsushita, Y.; Takeda, K.; Imada, T.; Michisita, M. 1977: Sequence and method of education of patients with diabetes mellitus: a case studied at a research group for management of diabetes mellitus Kango Tenbo. Japanese Journal of Nursing Science 2(5): 40-44
Tursunov, B.; Mazovetskiĭ, A.G.; Zavadskiĭ, P.S. 1978: Disturbed glucose tolerance and diabetes mellitus in the relatives of patients with the juvenile form of diabetes mellitus Problemy Endokrinologii 24(5): 13-16
Xia, H.; He, R.; Chen, J. 1996: Protective effect of angiotensin coverting enzyme inhibitor on renal function in normotensive non-insulin dependent diabetes mellitus patients with early diabetic nephropathy and microalbuminuria Zhonghua Nei Ke Za Zhi 35(8): 533-536
Taylor, B.S.; Hunt, G.; Abrams, E.J.; Coovadia, A.; Meyers, T.; Sherman, G.; Strehlau, R.; Morris, L.; Kuhn, L. 2011: Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa AIDS research and human retroviruses 27(9): 945-956
Lo, Y.-C.; Chen, M.-Y.; Sheng, W.-H.; Hsieh, S.-M.; Sun, H.-Y.; Liu, W.-C.; Wu, P.-Y.; Wu, C.-H.; Hung, C.-C.; Chang, S.-C. 2009: Risk factors for incident diabetes mellitus among HIV-infected patients receiving combination antiretroviral therapy in Taiwan: a case-control study HIV Medicine 10(5): 302-309
Parakh, M.Kumar.; Kasi, A.; Ayyappan, V.; Subramani, P. 2020: Knowledge and Awareness of Oral Manifestations of Diabetes Mellitus and Oral Health Assessment among Diabetes Mellitus Patients- A Cross Sectional Study Current Diabetes Reviews 16(2): 156-164
Piroth, L.; Grappin, M.; Waldner, A.; Sgro, C.; Duong, M.; Buisson, M.; Chavanet, P.; Portier, H. 1999: Discontinuing protease inhibitor treatment of HIV-1 patients for intolerance. Longitudinal study of 309 patients Presse Medicale 28(8): 381-387
Ozeki, I.; Karino, Y.; Toyota, J. 2011: Efficacy of the NS3-4A protease inhibitor telaprevir in patients with chronic hepatitis C Nihon Rinsho. Japanese Journal of Clinical Medicine 69(Suppl 4): 267-274
Traber, D.L.; Adams, T.; Sziebert, L.; Williams, P.; Traber, L.D. 1984: Failure of a protease inhibitor to affect the cardiopulmonary response to endotoxin when combined with a cyclooxygenase inhibitor Circulatory Shock 13(4): 319-323
Fehmann, H.C. 2001: The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office Fortschritte der Medizin. Originalien 119 Suppl. 2: 55-61
Fehmann, H.C. 2000: Treatment of type 2 diabetes mellitus with the alpha-glucosidase inhibitor Miglitol in the doctor's office Fortschritte der Medizin. Originalien 118 Suppl. 2: 55-61